5,3′-Dihydroxy-6,7,4′-trimethoxyflavanone exerts its anticancer and antiangiogenesis effects through regulation of the Akt/mTOR signaling pathway in human lung cancer cells

Chemico-Biological Interactions

Volumn 225, Issue , 2015, Pages 32-39

  Kim, Ki Mo ^a   Heo, Deok Rim ^a   Lee, Jun ^a   Park, Jong Shik ^a   Baek, Myung Gi ^a   Yi, Jin Mu ^a   Kim, Haejin ^a   Bang, Ok Sun ^a  

^a Korea Institute of Oriental Medicine (KIOM)   (South Korea)

Author keywords

5,3 Dihydroxy 6,7,4 trimethoxyflavanone; Akt; Angiogenesis; Apoptosis; Lung cancer cells

Indexed keywords

5,3'-DIHYDROXY-6,7,8,4'-TETRAMETHOXYFLAVANONE; FLAVANONE DERIVATIVE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MTOR PROTEIN, HUMAN; PROTEIN BAX; PROTEIN BCL 2; PROTEIN KINASE B; S6 KINASE; TARGET OF RAPAMYCIN KINASE; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ANIMAL; C57BL MOUSE; CARCINOMA, NON-SMALL-CELL LUNG; CELL SURVIVAL; DRUG EFFECTS; DRUG SCREENING; FEMALE; HUMAN; LUNG NEOPLASMS; METABOLISM; MOUSE; PHOSPHORYLATION; PHYSIOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL LINE; UMBILICAL VEIN ENDOTHELIAL CELL;

ANIMALS; BCL-2-ASSOCIATED X PROTEIN; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELL SURVIVAL; FEMALE; FLAVANONES; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; LUNG NEOPLASMS; MICE; MICE, INBRED C57BL; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-BCL-2; RIBOSOMAL PROTEIN S6 KINASES, 70-KDA; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES; VASCULAR ENDOTHELIAL GROWTH FACTOR A; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84914166835     PISSN: 00092797     EISSN: 18727786     Source Type: Journal    
DOI: 10.1016/j.cbi.2014.10.033     Document Type: Article

References (43)

1. A. Jemal, R. Siegel, J. Xu, and E. Ward Cancer statistics CA Cancer J. Clin. 60 2010 277 300
2. T.J. Lynch, A.A. Adjei, P.A. Bunn Jr., T.G. Eisen, J. Engelman, G.D. Goss, D.A. Haber, J.V. Heymach, P.A. Jänne, B.E. Johnson, D.H. Johnson, R.C. Lilenbaum, M. Meyerson, A.B. Sandler, L.V. Sequist, J. Settleman, K.K. Wong, and C.S. Hart Summary statement: novel agents in the treatment of lung cancer: advances in epidermal growth factor receptor-targeted agents Clin. Cancer Res. 12 2006 4365S 4371S
3. J. Folkman Angiogenesis in cancer, vascular, rheumatoid and other disease Nat. Med. 1 1995 27 31
4. J. Folkman What is the evidence that tumors are angiogenesis dependent? J. Natl. Cancer Inst. 82 1990 4 6
5. P.H. Maxwell, G.U. Dachs, J.M. Gleadle, L.G. Nicholls, A.L. Harris, I.J. Stratford, O. Hankinson, C.W. Pugh, and P.J. Ratcliffe Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth Proc. Natl. Acad. Sci. USA 94 1997 8104 8109
6. J.A. Forsythe, B.H. Jiang, N.Y. Lyer, F. Agani, S.W. Leung, R.D. Koos, and G.L. Semenza Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1 Mol. Cell. Biol. 16 1996 4604 4613
7. D.J. Hicklin, and L.M. Ellis Role of the vascular endothelial growth pathway in tumor growth and angiogenesis J. Clin. Oncol. 23 2005 1011 1027
8. A.K. Olsson, A. Dimberg, J. Kreuger, and L. Claesson-Welsh VEGF receptor signaling in control of vascular function Nat. Rev. Mol. Cell. Biol. 7 2006 359 371
9. S.C. Land, and A.R. Tee Hypoxia-inducible factor-1 alpha is regulated by the mammalian target of rapamycin (mTOR) via an mTOR signaling motif J. Biol. Chem. 282 2007 20534 20543
10. C.D. Befani, P.J. Vlachostergios, E. Hatzidaki, A. Patrikidou, S. Bonanou, and G. Simos Bortezomib represses HIF-1a protein expression and nuclear accumulation by inhibiting both PI3K/Akt/TOR and MAPK pathways in prostate cancer cells J. Mol. Med. 90 2012 45 54
11. N. Gao, M. Ding, J.Z. Zheng, Z. Zhang, S.S. Leonard, and K.J. Liu Vanadate-induced expression of hypoxia-inducible factor 1a and vascular endothelial growth factor through phosphatidylinositol 3-kinase/Akt pathway and reactive oxygen species J. Biol. Chem. 277 2002 31963 31971
12. J. Chen Multiple signal pathways in obesity-associated cancer Obes. Rev. 12 2011 1063 1070
13. P. Liu, H. Cheng, T.M. Roberts, and J.J. Zhao Targeting the phosphoinositide 3 kinase pathway in cancer Nat. Rev. Drug Discov. 8 2009 627 644
14. N. Hay The Akt-mTOR tango and its relevance to cancer Cancer Cell 8 2005 179 183
15. M. Ono, T. Yanaka, M. Yamamoto, Y. Ito, and T. Nohara New diterpenes and norditerpenes from fruit of Vitex rotundifolia J. Nat. Prod. 65 2002 537 541
16. E. Okuyama, K. Suzumura, and M. Yamazaki Pharmacologically active compounds of Viticis Fructus (Vitex rotundifolia) I. The components having vascular relaxation effects Nat. Med. 52 1998 218 225
17. H.J. Kim, J.M. Yi, N.O. Kim, Y.J. Lee, J.H. Kim, D.S. Oh, S.M. Oh, O.S. Bang, and J. Lee Cytotoxic compounds from the Fruits of Vitex rotundifolia against human cancer cell lines J. Korean Soc. Appl. Biol. 55 2012 433 437
18. R.A. Im, Y.H. Kim, M.R. Uddin, H.W. Lee, S.W. Chae, Y.H. Kim, W.S. Jung, B.J. Kang, C.S. Mun, and M.Y. Lee Scutellaria baicalensis extracts and flavonoids protect rat L6 cells from antimycin A-induced mitochondrial dysfunction Evid. Based Complement. Altern. Med. 2012 2012 517965 517972
19. S. Kumar, A.S. Pathania, A.K. Saxena, R.A. Vishwakarma, A. Ali, and S. Bhushan The anticancer potential of flavonoids isolated the stem bark of Erythrina suberosa through induction of apoptosis and inhibition of STAT signaling pathway in human leukemia HL-60 cells Chem. Biol. Interact. 205 2013 128 137
20. O.H. Lee, Y.M. Kim, Y.M. Lee, E.J. Moon, D.J. Lee, J.H. Kim, K.W. Kim, and Y.G. Kwon Sphingosine 1-phosphate induces angiogenesis: its angiogenic action and signaling mechanism in human umbilical vein endothelial cells Biochem. Biophys. Res. Commun. 264 1999 743 750
21. H. Harada, S. Itasaka, S. Kizaka-Kondoh, K. Shibuya, A. Morinibu, K. Shinomiya, and M. Hiraoka The Akt/mTOR pathway assures the synthesis of HIF-1alpha protein in a glucose- and reoxygenation-dependent manner in irradiated tumors J. Biol. Chem. 284 2009 5332 5342
22. M. Miyazawa, M. Yasuda, M. Fujita, H. Kajiwara, K. Hirabayashi, S. Takekoshi, T. Hirasawa, M. Murakami, N. Ogane, K. Kiguchi, I. Ishiwata, M. Mikami, and R.Y. Osamura Therapeutic strategy targeting the mTOR-HIF-1alpha-VEGF pathway in ovarian clear cell adenocarcinoma Pathol. Int. 59 2009 19 27
23. C. Leo, A.J. Giaccia, and N.C. Denko The hypoxic tumor microenvironment and gene expression Semin. Radiat. Oncol. 14 2004 207 214
24. J. Zhao Nutraceuticals, nutritional therapy, phytonutrients, and phytotherapy for improvement of human health: a perspective on plant biotechnology application Recent Pat. Biotechnol. 1 2007 75 97
25. J.J. McKnight, S.B. Gray, H.F. O'Kane, S.R. Johnson, and K.E. Wiliamson Apoptosis and chemotherapy for bladder cancer J. Urol. 173 2005 683 690
26. M. Dowsett, C. Archer, L. Assersohn, R.K. Gregory, P.A. Ellis, J. Salter, J. Chang, P. Mainwaring, I. BoeddinghausI, S.R. Johnston, T.J. Powles, and I.E. Smith Clinical studies of apoptosis and proliferation in breast cancer Endocr. Relat. Cancer 6 1999 25 28
27. B.M. Slomovitz, and R.L. Coleman The PI3K/AKT/mTOR pathways as a therapeutic target in endometrial cancer Clin. Cancer Res. 1 2012 5856 5864
28. X. Zhang, X.R. Li, and J. Zhang Current status and future perspectives of PI3K and mTORinhibitor as anticancer drugs in breast cancer Curr. Cancer Drug Targets 13 2013 175 187
29. J. Wu, C. Chen, and K.N. Zhao Phosphatidylinositol 3-kinase signaling as a therapeutic target for cervival cancer Curr. Cancer Drug Targets 13 2013 143 156
30. X.F. Huang, and J.Z. Chen Obesity, The PI3K/Akt signal pathway and colon cancer Obes. Rev. 10 2009 610 616
31. T.A. Yap, M.D. Garett, M.I. Walton, F. Raynaud, J.S. de Bono, and P. Workman Targeting the PI3K-Akt-mTOR pathway: progress, pitfalls, and promises Curr. Opin. Pharmacol. 8 2008 393 412
32. B.T. Hennessy, D.L. Smith, P.T. Ram, Y. Lu, and G.B. Mills Exploiting the PI3K/Akt pathway for cancer drug discovery Nat. Rev. Drug Discov. 4 2005 988 1004
33. C.H. Sun, Y.H. Chang, and C.C. Pan Activation of the PI3K/Akt/mTOR pathway correlates with tumors progression and reduced survival in patients with urothelial cells carcinoma of the urinary bladder Histopathology 58 2011 1054 1063
34. G.L. Semenza Targeting HIF-1for cancer therapy Nat. Rev. Cancer 3 2003 721 732
35. B.H. Jiang, and L.Z. Lin PI3K/PTEN signaling in angiogenesis and tumorigenesis Adv. Cancer Res. 102 2009 19 65
36. J. Kajar, and A. Maity PI3K/Akt/mTOR pathway in angiogenesis Front. Mol. Neurosci. 4 2011 1 8
37. S. Huang, and P.J. Houghton Targeting mTOR signaling for cancer therapy Curr. Opin. Pharmacol. 3 2003 371 377
38. T. Hellwig-Bürgel, D.P. Stiehl, A.E. Wagner, E. Metzen, and W. Jelkmann Review: hypoxia-inducible factor-1 (HIF-1): a novel transcription factor in immune reactions J. Interferon Cytokines Res. 25 2005 297 310
39. L. Lu, F. Payvandi, L. Wu, L.H. Zhang, R.J. Hariri, H.W. Man, R.S. Chen, G.W. Muller, C.C. Hughes, D.I. Stirling, P.H. Schafer, and J.B. Bartlett The anti-cancer drug lenalidomide inhibits angiogenesis and metastasis via multiple inhibitory effects on endothelial cell function in normoxic and hypoxic conditions Microvasc. Res. 77 2009 78 86
40. M. Graupera, J. Guillermet-Guibert, L.C. Foukas, L.K. Phng, R.J. Cain, A. Salpekar, W. Pearce, S. Meek, J. Millan, P.R. Cutillas, A.J. Smith, A.J. Ridley, C. Ruhrberg, H. Gerhardt, and B. Vanhaesebroeck Angiogenesis selectively requires the p110 alpha isoform of PI3K to control endothelial cells migration Nature 453 2008 662 666
41. K.T. Lin, J.C. Lien, C.H. Chung, S.C. Kuo, and T.F. Huang Bp5250 inhibits vascular endothelial growth factor-induced angiogenesis and HIF-1α expression on endothelial cells, Naunyn. Schmiedebergs Arch. Pharmacol. 385 2012 39 49
42. H.H. Lin, C.W. Tsai, F.P. Chou, C.J. Wang, S.W. Hsusa, C.K. Wang, and J.H. Chen Andrographolide down-regulates hypoxia-inducible factor-1 α in human non-small cell lung cancer A549 cells Toxicol. Appl. Pharmacol. 250 2011 336 345
43. J. Fang, Q. Zhou, L.Z. Lin, C. Xia, X. Hu, X. Shi, and B.H. Jiang Apigenin inhibits tumor angiogenesis through decreasing HIF-1 α and VEGF expression Carcinogenesis 28 2007 858 864